Preclinical Medications Discovery and Abuse Liability Testing for NIDA

NOTICE OF A PROPOSED CONTRACT ACTION NON-COMPETITIVE Notice ID: 75N95022C00004 Contract Opportunity Type: Presolicitation Response Date: November 27, 2026, at 1:00 PM Eastern Time (15 days) Classification: No Small Business Set Aside Used Product Service Code: AN11 NAICS Code: 541715 Place of Performance: Blank Description PURSUANT TO RFO 5.101 — PRESOLICITATION NOTICE, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION. THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022C00004 WITH VIRGINIA COMMONWEALTH UNIVERSITY. THIS IS NOT A SOLICITATION OR A REQUEST FOR COMPETITIVE PROPOSALS. The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), through the Addiction Treatment Discovery Program (ATDP) within NIDA’s Division of Therapeutics and Medical Consequences (DTMC), intends to modify Single Award Contract No. 75N95022C00004, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA,” to extend the period of performance by 12-months through February 21, 2027. All other terms and conditions remain unchanged. This modification will allow for the continuation of ongoing research conducted under the Preclinical Medications Discovery and Abuse Liability Testing program for NIDA and prevent any delays or disruption to the development of therapeutics essential for ongoing and upcoming pre-clinical and clinical trials while a new contract is properly planned and competed. REGULATORY AUTHORITY The resultant modification will include all applicable provisions and clauses of the Revolutionary FAR Overhaul (RFO) Initiative, in accordance with Executive Order 14275 and OMB Memorandum M-25-26. STATUTORY AUTHORITY This modification is conducted under the authority of 41 U.S.C. 3304(a)(1) and in accordance with RFO 6.103-1 Only one responsible source and no other supplies or services will satisfy agency requirements. CLOSING STATEMENT THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interest